top of page

April 28, 2022

SapereX registry launched  

SapereX, a comprehensive analysis of cellular and immune senescence, is now available in select clinics as part of an IRB-approved registry of healthy aging. Participants can now track the dynamic relationship between their health actions and these pillars of healthy aging and longevity 

Screen Shot 2022-05-26 at 4.07.15 PM.png

April 27, 2022

Aging study enrolls in record time

Immense community interest fueled rapid enrollment in our natural aging study conducted in partnership with Georgia Tech and UNC. Nearly 250 patients were enrolled in under three months, a record for all partners.                                                                            

April 12, 2022

SENSE study actively enrolling 

The SENSE study has commenced to validate Sapere Bio's discovery that pre-treatment measurement of cellular senescence can predict the risk of chemotherapy-induced peripheral neuropathy in early stage breast cancer patients                                               

Screen Shot 2021-11-04 at 11.56.21 AM.png

September 15, 2021

Senescence and aging biomarkers to predict CIPN

NIA awarded Sapere Bio a $2M SBIR (Small Business Innovation Research) grant to develop a clinical product to predict risk of chemothearpy-induced peripheral neuropathy using measures of cellular senescence

Screen Shot 2021-11-04 at 11.48_edited.jpg

July 19, 2021

Natural aging study funded by NIA

In partnership with Sapere Bio, Georgia Tech and UNC were awarded a grant from NIA to design a computational model of cellular senescence dynamics across the human lifespan. Read more here

Screen Shot 2021-11-04 at 12.26_edited.jpg

June 2021

Baltimore Longitudinal Study of Aging (BLSA)

Sapere Bio is the sole provider of cellular senescence measurements for the longest running study of human aging, the Baltimore Longitudinal Study of Aging led by Luigi Ferrucci and the NIA

Screen Shot 2020-08-21 at 3.56.18 PM.png

September 7, 2020


Sapere Bio was selected by the NIH to participate and present at the RESI conference to advance commercial development of innovative technologies 


August 25-27, 2020

NextGen Advancing Diagnostics Virtual Global Summit

Connect with us at NextGen Dx, promising in-depth insights from diagnostics leaders, regulators and reimbursement experts

Screen Shot 2020-08-21 at 4.55.37 PM.png

August 24, 2020

Accelerated aging and senescence linked in childhood cancer survivors

New data from Smitherman and colleagues at UNC, utilizing Sapere Bio technology, demonstrates the role of p16 in chemotherapy-accelerated aging, frailty and sarcopenia

Meeting Room

July 26, 2020

Sapere Bio expands headquarters in RTP, NC

Doubled office space at "Frontier" headquarters in Research Triangle Park, a entrepreneurial biotech hub

Blood Test

February 25, 2020

Enrollment opens for GUARD-AKI Validation Trial 

Multi-site clinical trial of AKI-Sapere commences, supported by NIA Phase 2 SBIR funding 

Screen Shot 2020-08-21 at 2.06.35 PM.png

February 24-27, 2020

25th Annual AKI and CRRT Conference

Updated data presented at leading international conference on acute kidney injury


March 1, 2019

15th Annual Biomarkers in Heart Failure and ACS Conference

15th Annual Biomarkers in Heart Failure and ACS meeting in La Jolla, CA.

Screen Shot 2019-03-05 at 11.41.49 AM_ed

February 26-28, 2019

24th Annual AKI and CRRT Conference

Poster presented with new data demonstrating senescence can stratify patients by risk of AKI before either CABG or cath/PCI.

Screen Shot 2019-02-19 at 2.27.31 PM_edi

February 13, 2019

WRAL TechWire Profiles Sapere Bio

Screen Shot 2019-02-19 at 2.55.41 PM.png

January 1, 2019

HealthSpan Dx Renamed Sapere Bio

Sapere derives from the Latin meaning "to know." 

geriatric onc

November 30, 2018

2018 Geriatric Oncology Symposium 

Natalia Mitin (HealthSpan CEO), Hyman Muss, Andrew Smitherman, and Kirsten Nyrop (UNC clinicians) presented on p16 applications in oncology. More info

Screen Shot 2019-03-05 at 11.32.58 AM_ed

October, 2018

HealthSpan Dx Awarded Multi-Year SBIR Grant

HealthSpan Dx receives multi-year SBIR (Small Business Innovation Research) grant from the NIH and National Institute on Aging (NIA)

PMWC2018_NMspeaker copy_edited.jpg

September 23-34, 2018

Precision Medicine World Conference 2018 Duke

Natalia Mitin, HealthSpan Dx CEO, presented "Bringing Biomarkers of Aging Into the Clinic."


October 1, 2018

HealthSpan Dx Moves to The Frontier

HealthSpan Dx tripled office and lab space with a move to custom-designed suites on the Frontier campus.


May 17, 2018

RTP180 Presents: HealthSpan Diagnostics 

Natalia Mitin provided an overview of our work and history for RTP180, a seminar on entrepreneurship.

bottom of page